This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Ectopic expression of neurotrophic peptide derived from
saposin C increases proliferation and upregulates androgen
receptor expression and transcriptional activity in human
prostate cancer cells
Yan Ding1, Hui-Qing Yuan1, Feng
Kong1, Xiao-Yan Hu1, Kai
Ren1, Jie Cai1, Xiao-Ling
Wang1, Charles Y. F. Young2
1Department of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan 250012, China
2Departments of Urology and Biochemistry and Molecular Biology, Mayo Graduate School, Mayo Clinic, Rochester, MN
55905, USA
Abstract
Aim: To determine the effects of the functional domain of saposin C (neurotrophic peptide [NP]) on androgen
receptor (AR) expression and transcriptional
activity. Methods: We constructed DNA vectors expressing NP or a
chimeric peptide of the viral TAT transduction domain and NP (TAT-NP) using gene cloning
technology. The effects of ectopic expression of NP or TAT-NP on cell growth were examined by 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl-2H-tetrazolium bromide (MTT) assay. Reverse transcription-polymerase chain reaction (RT-PCR), Western blot,
transient transfection and reporter gene assays were used to determine the effects of NP on AR expression and
activation. Results: NP stimulated proliferation of androgen responsive LNCaP cells in the absence of androgens.
RT-PCR and Western blot analyses showed that ectopic expression of NP resulted in induction of AR gene expression,
and that the NP-stimulated expression of AR could be synergistically enhanced in the presence of androgens.
Furthermore, reporter gene assay results showed that NP could enhance AR transactivation by increasing
androgen-inducible gene reporter
activity. Conclusion: We provided evidence that ectopic expression of saposin C-originated
NP could upregulate AR gene expression and activate the AR transcriptional function in an androgen-independent
manner in prostate cancer cells. (Asian J Androl 2007 Sep; 9: 601_609)
Keywords: neurotrophic peptide; androgen receptor; saposin C; prostate carcinoma cell lines
Correspondence to: Dr Hui-Qing Yuan, Department of Biochemistry and Molecular Biology, School of Medicine, Shandong University,
Wenhua West Road 44, Jinan 250012, China.
Tel: +86-531-8838-2092 Fax: +86-531-8838-2019
E-mail: lyuanhq@sdu.edu.cn
Received 2007-01-09 Accepted 2007-06-06
DOI: 10.1111/j.1745-7262.2007.00328.x
1 Introduction
A tremendous amount of information supports the roles of androgens and androgen receptors (AR) in the
development and progression of prostate cancer (PCa) [1, 2]. AR expression has been observed in primary, metastatic and
hormone-refractory malignant stages of PCa. Molecular mechanisms that delineate the roles of AR in the
development of recurrent hormone-refractory tumors have been proposed, including alterations in the AR gene mutations,
amplification, or cross-talk with signal pathways that can be initiated by certain growth factors or cytokines [3_5].
As a consequence, growth factors are also implicated in the activation of AR in addition to androgens, and it is
generally accepted that gain of function of AR activity
appears to be essential for outgrowth and survival of
hormone-refractory PCa.
Prosaposin is a highly conserved glycoprotein and
the precursor of four small heat-stable sphingolipid
activator proteins (saposin A, B, C and D), which are
required for the enzymatic hydrolysis of sphingolipids in
lysosomes [6]. As a neurotrophic factor in
vivo and in vitro, the functional sequence of prosaposin is localized
at the amino terminal end (14_22 residues) of saposin C.
Several synthetic peptides, including prosaptide TX14A
derived from this region, are equally bioactive as
prosaposin [6_8]. Prosaposin, saposin C and prosaptides
are proposed to exert their neurotrophic effects by
binding to a putative high affinity G protein-coupled receptor
(GPCR) [8] and thus they induce cell differentiation and
prevent cell death in neuroglial-derived cells [9, 10]. In
addition, prosaposin is also expressed as a secretory protein
in various cell types and body fluids, including blood,
seminal plasma, seminiferous tubular fluid and prostatic
secretions [6]. The inactivation of the prosaposin gene
affects the development of the prostate gland,
suggesting that prosaposin plays an important role in formation
of prostate at early stage [11]. Recently, prosaposin
overexpression has been observed in PCa cells, tissues
and xenografts [12]. Prosaposin, saposin C and prosaptide
TX14A can stimulate PCa cell growth, migration and
invasion through the activation of MAPK and PI3/AKT
signal pathways [13_15]. Furthermore, Koochekpour
et al. [16] reported that addition of prosaposin and saposin
C resulted in activation of AR in LNCaP cells in the
absence of androgens. Our main goal in the present study
was to investigate whether ectopic expression of
neurotrophic domain of saposin C could regulate AR
expression and activity in PCa cells. To test this possibility, we
constructed expression vectors encoding the neurotrophic
sequence of saposin C (neurotrophic peptide [NP]).
2 Materials and methods
2.1 Plasmid construction
Based on the functional domain sequence (14-mer
peptide, TKLINDDKTEKEIL) of saposin C [17], we synthesized two complementary NP oligonucleotides
containing KpnI and ApaI restriction enzyme sites at 5' and
3' ends, respectively and they are
5'-catgaccaagctgattgacaacaacaagactgagaaagaaatactctaataggggcc-
3' (sense) and 5'-CCTATTAGAGTATTTCTTTCTCAGTCTTGTTGTTGTCAATCAGCTTGG
TCATGGTAC-3' (antisense). After annealing, the DNA
fragment was inserted into pcDNA3.1 (+) and designated as pcDNA-NP. Similarly, double stranded DNA
fragment was synthesized as above, containing a TAT
protein transduction domain (TAT) sequence derived
from HIV-1 and followed by the NP sequence. TAT was
a transmembrane signal peptide and assumed to help NP
run across cell membrane. An alanine was inserted
between TAT and NP, serving as a hinge of two functional
regions. Two complementary sequences containing HindIII and XbaI sites at 5' and 3' ends, respectively,
were as follows:
5'-AGCTTATGTACGGCAGGAAGAAGCGTCGTCAGCGCAGGCGCGGTaccaagctgattgacaacaacaagactgagaaagaaatactctaatagT-3'(sense) and 5'-CTAGACTATTA
GAGTATTTCTTTCTCAGTCTTGTTGTTGTCAATCAGCTTGGTACCGCGCCTGCGCTGACGACGCTTCTTCCTGCCGTACATA-3' (antisense). The annealed DNA fragment was cloned into pcDNA3.1 (+) to
generate the pcDNA-TAT-NP plasmid. The authenticity of
the above recombinant plasmids was confirmed by direct sequencing.
2.2 Cell culture and chemicals
Human PCa cell lines, LNCaP (The American Type Culture Collection, Rochville, MD, USA), PC3 and DU145
(The Cell Bank of Chinese Academy of Sciences, Shanghai, China) were routinely cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum and
10% newborn bovine serum, respectively, until reaching
approximately 50_70% confluence. The cells were
maintained in serum-free RPMI 1640 medium for 24 h to
deplete endogenous steroid hormones before experiments.
Unless specified otherwise, treatment with mibolerone
(Mib, New England Nuclear), a synthetic androgen, was
carried out for 24 h after transfection. Mib was
dissolved in ethanol, and ethanol was also used as a control
vehicle.
2.3 Cell proliferation assay
PC3 and DU145 cells were seeded in 96-well plates at
a density of
0.5 × 104 cells/well, and LNCaP cells were
seeded in 24-well plates at a density of
3 × 104 cells/well. The cells were cultured under the conditions described
above. The expression vector pcDNA-NP (0.2 μg/well in
96-well plates, 0.8 μg/well in 24-well plates), or
pcDNA-TAT-NP (0.2 μg/well in 96-well plates,
0.8 μg/well in 24-well plates) was transfected into cells with Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) transfection reagent.
The parental vector pcDNA3.1 (+) (0.2 μg/well in
96-well plates, 0.8 μg/well in 24-well plates) served as a
negative control. After transfection, the cells were
maintained in serum-free RPMI 1640 medium for an
additional 24, 48 and 72 h. The number of living cells was
determined by 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl-2H-tetrazolium bromide (MTT) assay. Six replicates
were used for each treatment and the assay was repeated
at least three times.
2.4 RNA extraction and RT-PCR analysis
PC3 and LNCaP cells were seeded in 6-well plates
as described above. After transfection of pcDNA-NP
(4.0 μg/well), or pcDNA-TAT-NP (4.0 μg/well), the cells
were maintained in the serum-free medium for an
additional 24 h. Removal of the media was followed by a
brief rinse with 1 mL cold phosphate buffered saline
(PBS). The cells were used for total RNA extraction
with TRIzol Reagent as specified by the manufacturer
(Invitrogen, Carlsbad, CA, USA). Total RNA was treated
with DNase I (Takara, Dalian, China) to degrade plasmid
DNA. The first-strand synthesis of cDNA was made with
5 μg of total RNA and random hexamer primers using the RevertAid First-Strand cDNA Synthesis kit
(Fermentas, Burlington, Ontario, Canada). Polymerase
chain reaction (PCR) was then carried out under the
following conditions: 28 cycles at 95ºC for 60 s, 58ºC for
60 s, 72ºC for 1.5 min, with a final 10-min extension
cycle at 72ºC. Taq polymerase (Takara, Dalian, China)
was used to detect desired genes in transcript abundance.
Primers were synthesized by Invitrogen Corporation
(Invitrogen). The oligonucleotides primers for NP and
TAT-NP expression were as follows:
5'-TAATACGACTCACTATAGGG-3' (T7 promoter primer), and
5'-TAGAAGGCACA GTCGAGG-3' (pcDNA3.1/BGH reverse
terminator primer). The expected lengths of PCR products are
pcDNA-TAT-NP (193 bp), pcDNA-NP (157 bp) and pcDNA3.1 (+) (180 bp). The primers for AR gene
transcript were: 5'-TTGGAGACTGCCAGGGAC-3' (forward),
and 5'-TCAGGGGCGAAGTAGAGC-3' (reverse) (686 bp, according to the human AR sequence from the
NCBI/genome data bank). The primers for the β-actin
transcript were (359 bp, based on β-actin cDNA
sequences from the NCBI/genome data bank): 5'-ACCAACTGGGACGACAT-3' (forward) and 5'-CG
CTCGGTGAGGATCTTCAT-3' (reverse).
The PCR products were confirmed as a single band
through 1.2% agarose gel electrophoresis and
normalized with β-actin. The experiments were repeated for at
least three times independently and each PCR experiment
included non-template control.
2.5 Western blot analysis
PC3 and LNCaP cells were seeded in 75 mL culture
flasks using the same treatment described above.
Removal of the media was followed by a brief rinse with
3 mL cold PBS, and cell pellets were obtained by
centrifugation. Whole cell lysates were prepared
according to the method described previously [18]. Freshly
prepared protease inhibitors (0.5 mmol/L
phenylmethanesulfonyl fluoride (PMSF), 50 μg/mL aprotinin,
1 mmol/L sodium orthovanadate, 10 mmol/L sodium
fluoride and 10 mmol/L β-glycerolphosphate) were also
added. The Bradford protein assay (Bio-Rad, Hercules,
CA, USA) was used for quantifying the protein content.
Fifty micrograms of protein for each sample was
separated on an SDS polyacrylamide gel (8%), and the gel
was electrotransferred onto a nitrocellulose membrane
(Bio-Rad, Hercules, CA, USA) for Western analysis. The
blots were blocked with 5% non-fat milk in TBST buffer
(20 mmol/L Tris-HCl, 137 mmol/L NaCl, and 0.1%
Tween 20, pH 8.0) prior to incubation with specific
antibody of AR (BD Biosciences, 554225) or β-actin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at
room temperature. After washing with TBST buffer for
three times, the membranes were incubated with an
anti-rabbit or anti-mouse IgG secondary antibody conjugated
to horseradish peroxidase (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at room temperature for 1 h and
visualized by enhanced chemiluminescence substrate
(ECL, Amersham, Arlington Heights, IL, USA).
2.6 Transient transfection and reporter gene activity
assays
PC3 and LNCaP cells were incubated in 24-well plates
under the conditions described above for 48 h before
transfection. For transfection into LNCaP cells, pGL3
basic vector with 6-kb prostate-specific antigen (PSA)
promoter (PSA promoter-Luc, 0.8 μg/well), or
pGL3-SV40 with three copies of androgen response elements
(ARE) of hk2 gene (hk2-3ARE-Luc, 0.8 μg/well) [18], and
pcDNA-NP (0.3 μg/well) or pcDNA-TAT-NP
(0.3 μg/well) were cotransfected with Lipofectamine 2000. For
transfection into PC3 cells, the human AR expression vector
pSG5-hAR (0.2 μg/well) was included for cotransfecting
with the plasmids described above. The parental
vectors pcDNA3.1 (0.3 μg/well), pGL3 basic
(0.8 μg/well) and pGL3-SV40 (0.8 μg/well) were used as controls.
The phRL-TK vector (0.1 μg/well, Renilla luciferase,
Promega, Madison, WI, USA) served as an internal
control to normalize transfection efficiency. Twenty-four
hours after transfection, cells were either treated with
1 nmol/L of Mib or remained untreated for an additional
24 h in serum-free medium. Cell extracts were prepared
and used for dual-luciferase assay (Dual-Luciferase
Reporter assay system, Promega, Madison, WI, USA). At
least three independent transfection experiments were
performed.
Statistical analysis was performed using the 2-tailed
Student's t-test. P < 0.05 was accepted as the level of
significance.
3 Results
3.1 Identification of NP mRNA expression in PCa cells
We first constructed expression vectors containing
NP or TAT-NP. Expression levels of NP and TAT-NP after transfection were investigated at mRNA level using
RT-PCR. The time course study revealed that the
plasmids of pcDNA-TAT-NP (lane 2 in Figure 1A) and
pcDNA-NP (lane 3 in Figure 1A) can be continuously
expressed at the three measured time points (12, 24 and
48 h) in LNCaP cells, which were maintained at least up
to 48 h, as shown in Figure 1A. No bands were seen in
the negative control (lane 1). The bands observed in
lane 4 were from a transcript containing the multiple clone
site sequence in pcDNA3.1 vector. It seemed that the
mRNA expression levels of NP and TAT-NP had no significant difference among various time-periods. The
mRNA expressions of NP and TAT-NP were further analyzed in PC3 cells. As shown in Figure 1B, the bands
could be observed in cells transfected with
pcDNA-TAT-NP (lane 2) and pcDNA-NP (lane 3) with a similar
expression pattern to that in LNCaP cells. These results
suggested that the plasmids of NP and TAT-NP can be
expressed in PCa cells.
3.2 NP stimulates PCa cell growth
To test proliferative ability of ectopic expression of
NP or TAT-NP, MTT assays were used to analyze the cell growth. The result in Figure 2A shows that
ectopically expressed NP and TAT-NP can stimulate
proliferation of LNCaP cells by 15% and 10% at 24 h, 14%
and 20% at 48 h, and 10% and 16% at 72 h, respectively,
as compared with the control group. It appeared that
there was no obvious difference between NP and
TAT-NP in terms of their proliferative stimulation activity. In
addition, stimulatory effects of NP on cell proliferation
were examined by using PC3 and DU145 cell lines, and
similar results were obtained as shown in Figure 2B and
2C. The NP and TAT-NP-stimulated effects were observed increased by 20% and 19% at 24 h, 15% and
21% at 48 h, 39% and 35% at 72 h on PC3 cells
(Figure 2B), whereas by 13% and 17% at 24 h, 7% and
20% at 48 h, and 24% and 34% at 72 h on DU145 cells
(Figure 2C). Taken together, the data showed that
expressions of NP could increase proliferation of prostate
cancer cells in the absence of androgens.
3.3 NP upregulates androgen receptor expression
AR plays an important role in the proliferation and
survival of PCa cells. Once the expression level of AR
was reduced or eliminated specifically, the cell
proliferation was consequently decreased [19]. In an attempt to
investigate whether AR expression could be affected by
NP, the AR mRNA and protein expression levels were
evaluated by RT-PCR and Western blot in LNCaP cells
following transfection of NP or TAT-NP. The time course
induction of AR mRNA expression was detected as early
as 12 h after transfection, and the bands in cells
transfected with TAT-NP (lane 1 in Figure 3A) and NP (lane 2
in Figure 3A) were all stronger than that of the control
(lane 3 in Figure 3A) in the absence of androgens. The
stronger induction by NP and TAT-NP were maintained
at least up to 48 h.
Protein expression levels are shown in Figure 3B.
The NP-mediated and TAT-NP-mediated induction of AR
protein expressions were observed in the absence of
androgens in LNCaP cells (lane 1 and lane 2 in Figure 3B,
respectively). Both NP and TAT-NP displayed some stimulatory effects on AR expression. In addition, the
NP-induced and TAT-NP-induced expressions of AR were further enhanced when cells were treated with Mib
following transfection. As seen in Figure 3C, the
synergistic effect of androgen and NP on the
expression of AR is evident (lanes 4 and 6, lanes 5 and 6), as compared with
Mib treatment alone. Furthermore, a human AR
expression vector pSG5-hAR was cotransfected with TAT-NP
or NP plasmid into PC3 cells to evaluate the NP
enhancing effect on AR expression. As expected, the result
(Figure 3D) shows that the AR protein expressions were
induced in cells cotransfected with TAT-NP (lane 1) or
NP (lane 2) in the absence of androgen, and less AR
protein was detected in the control group. These
findings suggest that NP and TAT-NP might upregulate AR
gene expression at the mRNA and protein levels.
3.4 NP enhances AR transcriptional activity
PSA and hk2 are androgen-inducible genes that
contain ARE to which AR binds. The expressions of PSA
and hk2 genes are highly dependent on
androgen-mediated activation of AR [18]. Next we examined whether
transactivation of AR could be modulated by NP
independent of androgens. The LNCaP cells were transiently
cotransfected with a PSA promoter luciferase reporter
and NP, or TAT-NP plasmid. The luciferase activities of
the reporter were monitored to show the AR
transactivation. As seen in Figure 4A, production of PSA promoter
reporter was observed in the cotransfection of NP or
TAT-NP plasmid without androgens, whereas basal luciferase activity of PSA promoter reporter was shown in
cotransfection of pcDNA3.1 plasmid. The strongest
induction of the PSA promoter reporter activity was
observed in response to androgen treatment, followed by
cotransfection of NP or TAT-NP. We then cotransfected
the human AR expression vector into AR-negative PC3
cell line with the PSA promoter reporter to verify the NP
effect on the AR transactivition. As seen in Figure 4B,
higher PSA promoter reporter activity was shown in the
cells cotransfected with NP or TAT-NP plasmid. To
further demonstrate the role of NP in regulation of AR
transactivity, hk2-3ARE-Luc vector containing three
tandem ARE in the hk2 promoter was used in the cotransfection experiment. The increased reporter
activities stimulated by NP or TAT-NP were observed in
both LNCaP (Figure 4C) and PC3 cells (Figure 4D). The
results are consistent with those in Figure 4A and 4B.
Because the reporter construct hk2-3ARE-Luc only
contains three copies of ARE, production of luciferase
activity induced by NP might result from stimulation of NP
on AR transactivation. The data suggest that the
stimulatory effect of NP on AR expression and transactivation
could be achieved by the transfection of NP expression
vector into prostate cancer cells in the absence of
androgen.
4 Discussion
Numerous reports revealed how diversity of AR
signaling could be modulated. Regulatory mechanisms,
including overexpression/amplification, mutations and
androgen-independent activation of AR, are all believed to
play important roles in the progression of
androgen-independence of PCa. Several growth factors have been
implicated in the induction of AR activity independent of
androgens. Recent data have indicated prosaposin and
its active derivatives (i.e. saposin C, prosaptide TX14A),
which have been known as neurotrophic factors [7], to
be functional as cell survival and anti-apoptotic factors
for PCa cells [13_15]. Subsequently, purified human
milk-prosaposin and recombinant saposin C were shown
to promote AR expression and activity [16]. Our present
study found that ectopically expressed NP, which
encoded the functional sequence of saposin C, stimulated
PC3, DU145 and LNCaP cell proliferation. Furthermore,
expression of NP was also involved in regulation of AR
expression and transcriptional function. The RT-PCR
and Western blot analyses results indicated that NP
increased AR gene expression (Figures 2 and 3) and
subsequently enhanced AR transcriptional activity in an
androgen-independent manner (Figure 4). These results
are consistent with the data obtained from synthesized
prosaptides or purified recombinant human saposin C
[13_16], which were added to cell culture media. In
addition, our results provide evidence that stimulatory
effect of NP on AR expression is synergistically enhanced
by androgen (Figure 3C); however, the NP-mediated
induction was less than that mediated by androgen treatment. It suggested that NP might play a role in
regulation of AR transactivity independent of androgens,
which might be achieved by its regulation of a complex
network and signaling pathways in PCa.
In sum, our observations indicate that NP, as a
growth stimulating peptide to PCa cells, exerted activity
by increasing the expression and enhancing the transactivation of AR in a ligand-independent manner.
Investigations focusing on how NP regulates AR will
provide further insight into its role in PCa progression
and a new cancer therapeutic target.
Acknowledgment
This work was supported by the Scientific
Technology Research Grant of the Ministry of Education of China
(No. 106101) and Shandong Scientific Reward Funding
Program (No. 2006BS03006).
References
1 Taplin ME, Balk SP. Androgen receptor: a key molecule in the
progression of prostate cancer to hormone independence. J
Cell Biochem 2004; 91: 483_90.
2 Suzuki H, Ito H. Role of androgen receptor in prostate cancer.
Asian J Androl 1999; 1: 81_5.
3 Feldman BJ, Feldman D. The development of
androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34_45.
4 Jenster G. Ligand-independent activation of the androgen
receptor in prostate cancer by growth factors and cytokines. J
Pathol 2000; 191: 227_8.
5 Culig Z. Androgen receptor cross-talk with cell signalling
pathways. Growth Factors 2004; 22: 179_84.
6 Kishimoto Y, Hiraiwa M, O'Brien JS. Saposins: structure,
function, distribution, and molecular genetics. J Lipid Res
1992; 33: 1255_67.
7 O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y.
Identification of prosaposin as a neurotrophic factor. Proc
Natl Acad Sci U S A 1994; 91: 9593_6.
8 Campana WM, Hiraiwa M, O'Brien JS. Prosaptide activates
the MAPK pathway by a G-protein-dependent mechanism
essential for enhanced sulfatide synthesis by Schwann cells.
FASEB J 1998; 12: 307_14.
9 Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O'Brien JS.
Cell death prevention, mitogen-activated protein kinase
stimulation, and increased sulfatide concentrations in Schwann
cells and oligodendrocytes by prosaposin and prosaptides.
Proc Natl Acad Sci U S A 1997; 94: 4778_81.
10 Campana WM, Hiraiwa M, Addison KC, O'Brien JS. Induction
of MAPK phosphorylation by prosaposin and prosaptide in
PC12 cells. Biochem Biophys Res Commun 1996; 229: 706_12.
11 Morales CR, Badran H. Prosaposin ablation inactivates the
MAPK and AKT signaling pathways and interferes with the
development of the prostate gland. Asian J Androl 2003; 5:
57_63.
12 Koochekpour S, Zhang YJ, Beroukhim R, Hsieh CL, Hofer
MD, Zhau HE, et al. Amplification and overexpression of
prosaposin in prostate cancer. Genes Chromosomes Cancer
2005; 44: 351_64.
13 Lee TJ, Sartor O, Luftig RB, Koochekpour S. Saposin C
promotes survival and prevents apoptosis via
PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer 2004; 3: 31.
14 Koochekpour S, Sartor O, Lee TJ, Zieske A, Patten DY,
Hiraiwa M, et al. Prosaptide TX14A stimulates growth,
migration, and invasion and activates the
Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate
2004; 61: 114_23.
15 Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W,
Remmel N, et al. Saposin C stimulates growth and invasion,
activates p42/44 and SAPK/JNK signaling pathways of
MAPK and upregulates uPA/uPAR expression in prostate
cancer and stromal cells. Asian J Androl 2005; 7: 147_58.
16 Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey
S, et al. Prosaposin upregulates AR and PSA expression and
activity in prostate cancer cells (LNCaP). Prostate 2007;
67:178_89.
17 Taylor EM, Otero DA, Banks WA, O'Brien JS. Designing
stable blood-brain barrier-permeable prosaptide peptides for
treatment of central nervous system neurodegeneration. J
Pharmacol Exp Ther 2000; 293: 403_9.
18 Yuan H, Gong A, Young CY. Involvement of transcription
factor Sp1 in quercetin-mediated inhibitory effect on the
androgen receptor in human prostate cancer cells.
Carcinogenesis 2005; 26: 793_801.
19 Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ.
Disruption of androgen receptor function inhibits proliferation of
androgen-refractory prostate cancer cells. Cancer Res 2002;
62: 1008_13.
|